Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15467435 | 1.00 | TRPM8 (0.46) | TRPM8TRPV1P2RY1RAB9ARET | |
| SCHEMBL15467600 | 0.90 | MTOR (0.48) | TRPM8TRPV1P2RY1RAB9ANPC1 | |
| SCHEMBL15467601 | 0.90 | MTOR (0.48) | TRPM8TRPV1P2RY1RAB9ANPC1 | |
| SCHEMBL15469445 | 0.90 | RAB9A (0.44) | TRPM8P2RY1RAB9ANPC1 | |
| SCHEMBL15467365 | 0.88 | EPHX2 (0.48) | TRPM8TRPV1RAB9ANPC1EPHX2 | |
| SCHEMBL15467364 | 0.88 | EPHX2 (0.48) | TRPM8TRPV1RAB9ANPC1EPHX2 | |
| SCHEMBL15467312 | 0.88 | TRPM8 (0.57) | TRPM8TRPV1RAB9ANPC1 | |
| SCHEMBL15467310 | 0.88 | TRPM8 (0.57) | TRPM8TRPV1RAB9ANPC1 | |
| SCHEMBL15466948 | 0.82 | TRPM8 (0.57) | TRPM8TRPV1RAB9A | |
| SCHEMBL15467675 | 0.82 | TRPM8 (0.57) | TRPM8TRPV1RAB9ANPC1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014025651-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | WO | claimed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | claimed |
| US-8952009-B2 | Chroman derivatives as TRPM8 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2014025651-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC. (US) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | TRPM8 1/4885TRPV1 11/4885P2RY1 81/4885 |
| US-20140045855-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | TRPM8 1/4885TRPV1 11/4885P2RY1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.